Met Life Investment Management, LLC Immunovant, Inc. Transaction History
Met Life Investment Management, LLC
- $18 Billion
- Q4 2024
A detailed history of Met Life Investment Management, LLC transactions in Immunovant, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 35,648 shares of IMVT stock, worth $980,676. This represents 0.01% of its overall portfolio holdings.
Number of Shares
35,648
Previous 33,608
6.07%
Holding current value
$980,676
Previous $924,000
6.06%
% of portfolio
0.01%
Previous 0.01%
Shares
41 transactions
Others Institutions Holding IMVT
# of Institutions
218Shares Held
67.1MCall Options Held
2.48MPut Options Held
561K-
Vanguard Group Inc Valley Forge, PA6.68MShares$184 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT6MShares$165 Million7.27% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD5.12MShares$141 Million0.08% of portfolio
-
Black Rock Inc. New York, NY4.92MShares$135 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY3.87MShares$106 Million1.5% of portfolio
About Immunovant, Inc.
- Ticker IMVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 129,077,000
- Market Cap $3.55B
- Description
- Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...